Activest Wealth Management’s Denali Therapeutics DNLI Stock Holding History

Activest Wealth Management’s Portfolio DNLI Stock Details DNLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-131	Closed	-$2.51K	–	1092
2024 Q4	$2.67K	Hold	131	–	–	﹤0.01%	416
2024 Q3	$3.82K	Hold	131	–	–	﹤0.01%	388
2024 Q2	$3.04K	Hold	131	–	–	﹤0.01%	376
2024 Q1	$2.69K	Hold	131	–	–	﹤0.01%	292
2023 Q4	$2.81K	Hold	131	–	–	﹤0.01%	254
2023 Q3	$2.7K	Hold	131	–	–	﹤0.01%	257
2023 Q2	$6.94K	Hold	131	–	–	﹤0.01%	204
2023 Q1	$2.87K	Hold	131	–	–	﹤0.01%	238
2022 Q4	$3.64K	Hold	131	–	–	﹤0.01%	375
2022 Q3	$4K	Hold	131	–	–	﹤0.01%	360
2022 Q2	$4K	Hold	131	–	–	﹤0.01%	272
2022 Q1	$4K	Hold	131	–	–	﹤0.01%	272
2021 Q4	$6K	Hold	131	–	–	﹤0.01%	244
2021 Q3	$7K	Buy	+131	New	+$7.38K	﹤0.01%	253

Other funds holding DNLI

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Activest Wealth Management's DNLI Position: Q1 2025 in Review

Activest Wealth Management sold out of Denali Therapeutics (DNLI) in Q1 2025, closing a stake of 131 shares — an estimated $2.51K sold.

Activest Wealth Management first reported a position in DNLI in Q3 2021 and held it in 14 quarters. The position peaked at $7K in Q3 2021. 222 funds tracked by Wall St. Rank hold DNLI as of Q1 2025.

Activest Wealth Management reported no remaining Denali Therapeutics position as of Q1 2025 after selling out during the quarter.
Activest Wealth Management sold 131 Denali Therapeutics shares in Q1 2025, an estimated $2.51K.
Activest Wealth Management first reported a position in Denali Therapeutics in Q3 2021 and held it in 14 quarters.
Activest Wealth Management's Denali Therapeutics position peaked at $7K in Q3 2021.
222 funds tracked by Wall St. Rank held Denali Therapeutics as of Q1 2025.

Based on Activest Wealth Management's 13F filing for Q1 2025, filed 15 May 2025.